Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Nov 11, 2026 · Filed Nov 12, 2026
The CEO of Larimar Therapeutics paid $50K out of pocket for Larimar Therapeutics shares. 6 other people at Larimar Therapeutics bought some too, in the same month. It was the first purchase in over a year.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$49,953
Shares × reported transaction price
$25K–$100K
+4.9%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
None in 16 months of history
Confirmed open-market purchases by the same insider in the available history
7 distinct insiders in 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
This purchase equals about 1.4% of the CEO's reported total pay for fiscal 2025 ($3.53M)
Purchase value ÷ the CEO's total from the Summary Compensation Table, as tagged in the pay versus performance table of the company's proxy statement (DEF 14A), filed 2026-04-20. The proxy names Dr. Ben-Maimon as CEO for that year. A size comparison, not a judgement
2 days after results of Nov 9, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $2.73 on Nov 11, 2026, 38% above its 52-week low and 54% below its high, after a 15% drop over the previous 30 trading days
52-week range $1.99 (Oct 16, 2026) to $5.95 (Feb 25, 2026), 19% of the way up, from 250 adjusted closes. 30 trading days earlier: $3.20 on Sep 30, 2026. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
6 LRMR insiders bought within the same week; no week in filings since 2014 had that many buyers. Carole Ben-maimon's first purchase of LRMR since May 2023
Compared with every open-market purchase and sale of this company in SEC filings since 2006. A fact about the record, not a signal to trade
Insider buying
7 insiders in a week, a first since 2014Traded Nov 12 · filed 1 day later
A Larimar Therapeutics director paid $187K out of pocket for Larimar Therapeutics shares. 6 other people at Larimar Therapeutics bought some too, in the same month.
Insider buying
6 insiders in a week, a first since 2014Traded Nov 11 · filed 1 day later
Larimar Therapeutics's Chief Development Officer paid $14K out of pocket for Larimar Therapeutics shares. 6 other people at Larimar Therapeutics bought some too, in the same month. It was the first purchase in over a year.
Insider buying
6 insiders in a week, a first since 2014Traded Nov 11 · filed 1 day later
The CFO of Larimar Therapeutics paid $50K out of pocket for Larimar Therapeutics shares. 6 other people at Larimar Therapeutics bought some too, in the same month. It was the first purchase in over a year.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.